There has been one change in the jury’s composition in the past couple of days-a young woman got dismissed for financial hardship, and was replaced with an alternate. Presumably, they do now have twelve people who are coming at this as clean slates. It must be interesting for you-the person who knows this story better than almost anybody on earth-to hear it told again, through this trial, to a jury that has never heard of Theranos or Elizabeth Holmes. I’ve been watching my in-box, expecting a subpoena to drop any day. So I would anticipate that at some point they’re going to subpoena me and call me to the stand. I’m planning to go back, at the very least, for the end of the trial and the verdict, but it’s possible-even likely-that I will have to go back before then, because I’m No. I was there for about eleven days for jury selection and then opening arguments. In our conversation, which has been edited for length and clarity, we discussed the likelihood that he’ll be called as a witness, the defense’s likely attempt to pin the blame on Balwani, and the danger of Silicon Valley’s fake-it-till-you-make-it ethos.Īre you at the trial in San Jose now, or are you back in New York? (She and her legal team have accused Carreyrou of advocacy journalism in bringing about Theranos’s collapse.) Holmes’s former boyfriend Ramesh (Sunny) Balwani, who was Theranos’s president and C.O.O., and has also pleaded not guilty, will be tried separately next year. If Holmes, who has pleaded not guilty, is convicted, she faces up to twenty years in prison, plus fines and restitution. He is currently hosting “Bad Blood: The Final Chapter,” a podcast that covers the trial and delves into some of the astonishing evidence the prosecution is likely to introduce in the coming months-the trial, now entering its third week, is expected to last until mid-December, or longer. Then, six years ago, the company collapsed like a soufflé, following a Wall Street Journal exposé by the reporter John Carreyrou, who wrote that the company’s supposedly revolutionary technology-a proprietary lab machine that could run hundreds of medical tests using mere drops of blood drawn from a finger prick-was not at all what Theranos claimed it to be.Ĭarreyrou’s explosive reporting became the basis for a 2018 book, “ Bad Blood,” which tracks the rise and fall of Theranos, from Holmes’s founding of the company as a nineteen-year-old Stanford dropout through her fall from grace. It employed upward of seven hundred people and had a board of directors stacked with the likes of Henry Kissinger and James Mattis. Theranos was once valued at more than nine billion dollars. of the now defunct medical-testing tech startup Theranos, began on August 31st, three years after Holmes’s indictment on numerous counts of fraud and conspiracy to commit wire fraud. The federal trial of Elizabeth Holmes, the founder and former C.E.O.

Elizabeth holmes today